Will AstraZeneca Beat These Analyst Estimates?
AstraZeneca (ISE: AZN) is expected to report Q3 earnings on Oct. 26. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict AstraZeneca's revenues will wither -17.6% and EPS will contract -15.8%.
The average estimate for revenue is $6.77 billion. On the bottom line, the average EPS estimate is $1.44.
Last quarter, AstraZeneca booked revenue of $6.66 billion. GAAP reported sales were 21% lower than the prior-year quarter's $8.43 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.53. GAAP EPS of $1.27 for Q2 were 17% lower than the prior-year quarter's $1.53 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 79.9%, 280 basis points worse than the prior-year quarter. Operating margin was 31.9%, 490 basis points worse than the prior-year quarter. Net margin was 24.2%, 90 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $28.28 billion. The average EPS estimate is $5.98.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 44 members out of 49 rating the stock outperform, and five members rating it underperform. Among one CAPS All-Star picks (recommendations by the highest-ranked CAPS members), one give AstraZeneca a green thumbs-up, and give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on AstraZeneca is hold, with an average price target of $46.69.
Can your portfolio provide you with enough income to last through retirement? You'll need more than AstraZeneca. Learn how to maximize your investment income and get "The 3 DOW Stocks Dividend Investors Need." Click here for instant access to this free report.
- Add AstraZeneca to My Watchlist.
The article Will AstraZeneca Beat These Analyst Estimates? originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool owns shares of AstraZeneca plc (ADR). Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.